Capital
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
Dimension Secures $500M for Second Fund, Focusing on the Intersection of Science and Technology
Dimension, Venture Capital, Science, Technology, Biotech, AI, Machine Learning, Life Sciences, Innovation
Alligator Bioscience Slashes 70% of Workforce Due to Financial Strains
Alligator Bioscience, staff cuts, capital constraints, biopharma industry, financial challenges
Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation
Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment
Bain Capital Raises $3 Billion for Fourth Life Sciences Fund to Support Innovative Biotech Startups
Bain Capital, Life Sciences Fund, Biotech Startups, Venture Capital, Funding
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures